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Vasopressin receptors in plasma membranes and on cell monolayers were treated with sulthydryl reagents. Specific binding of PH]AW to renal 
V, receptors in membranes from bovine and porcine kidney and on LLC-PK, cells was markedly (80-90~) reduced after treatment with NEM 
but that to V, receptors on rat liver membranes and A7r5 smooth muscle cells only slightly (l&30@. Inactivation of receptors by NEM reduced 
the number of binding sites without altering the alhnity of unmodified receptor molecules. High al%nity ligands (agonists and antagonists), in com- 
plex with the V, receptor, protected against its inactivation. The results suggest hat one or more cysteine residues are located in the ligand-binding 
site of the V, receptor, and are essential for hormone binding. Furthermore, it is possible to use NEM to differentiate between vasopressin isorecep- 
tors. 
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1. INTRODUCTION 
Two types of vasopressin receptor, with differing 
ligand specificity, second messenger system, and func- 
tion, have so far been characterised. Vi receptors, 
which are mainly found in vascular smooth muscle cells 
and in hepatocytes, play an important role in regulation 
of the vascular system and in carbohydrate metabolism. 
Vi receptors function via the phospholipase C signal 
transfer system. VZ receptors play a role in water 
resorption in the mammalian kidney collecting tubule 
and the amphibian urinary bladder. This process is 
mediated by cyclic AMP (for review see [l]). 
Several recent observations suggest that sulfhydryl 
reagents (e.g. NEM, p-CMBS, IAA) may modify 
vasopressin-induced water permeability [2-4]. In these 
studies, the effect of these cysteine-modifying reagents 
on receptor-ligand interaction was not investigated. 
Other types of membrane receptor (e.g. opiate, 
acetylcholine, adrenergic and dopaminergic receptors) 
have been shown to have altered ligand binding proper- 
ties after treatment with sulfhydryl reagents [5]. Bin- 
ding studies with mutant receptors produced by expres- 
sion of modified human &-adrenergic receptor genes 
showed that substitution of a number of conserved cys- 
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teine residues resulted in reduced affinity of the recep- 
tor for its ligand [6-71. 
In this report we demonstrate the effect of NEM 
and other sulfhydryl reagents on the binding properties 
of Vi and VZ vasopressin receptor subtypes in isolated 
membranes and intact cells. Vr receptors are relatively 
stable towards NEM whereas VZ receptors are very sen- 
sitive both to NEM and to the other sulfhydryl reagents 
tested. The inactivation of the VZ receptor, due to 
NEM, can be prevented by receptor-ligand complex 
formation prior to treatment with the sulfhydryl 
reagent. 
2. MATERIALS AND METHODS 
2.1. Materials 
[‘H]AVP (53.6 Ci/mmol) was purchased from Du Pont NEN, Bad 
Homburg FRG; p-CMBS, NEM and IAA were from Sigma Chemie 
GmbH, Deisenhofen FRG, [As~‘*~,Arg~]vasopressin was from Penin- 
sula Laboratories, Belmont, CA, USA. The other peptides were pro- 
duced by solid phase synthesis. All other chemicals were of analytical 
grade. 
2.2 Membrane preparations and receptor binding assays 
Bovine kidney inner medulla plasma membranes were prepared by 
a two-step centrifugation procedure [8]. The 10000 x g pellet 
resulting from this procedure had a specific binding capacity of ap- 
proximately 1.3 pmol [“H]AVP/mg protein. Porcine kidney mem- 
brane preparations obtained via a similar method [9] had a capacity 
of 0.55 pmol [“H]AVP/mg protein. Rat liver plasma membranes, 
containing 0.65 pmol Vi receptor/mg protein, were prepared using an 
aqueous two-phase polymer system [lo]. Binding tests with plasma 
membranes were performed by incubating membranes (containing 
100 pg of protein) in 100 pl of the corresponding binding buffer [8-lo] 
containing 10 nM [“HIAVP in presence (non-specific binding) or in 
the absence (total binding) of 1 PM AVP for 30 min at 30°C. To ter- 
minate the binding tests, the mixtures were diluted with 5 ml of ice- 
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cold washing buffer [8-lo], immediately filtered under vacuum 
through Whatman GF/F filters, and rinsed twice with 5 ml of ice-cold 
washing buffer. The filters were placed in counting vials with scintilla- 
tion liquid and analysed by liquid scintillation spectrometry. Protein 
determination was performed by means of modified fluorescamine 
assay Ill]. 
The effect of sulfhydryl reagents on specific binding was tested by 
performing the binding test after preincubation of the membranes 
(100 pg protein in 100 nl of binding buffer [S-lo]) with sulfhydryl 
reagents, with or without subsequent removal of the sulfhydryl 
reagents by ~nt~fugation prior to the binding test. In order to in- 
vestigate receptor-ligand complex stability, bovine kidney membranes 
(100 fig protein in 100 ~1 of binding buffer: 50 mM EPPS, 5 mM 
MgC12, pH 8.2 [8]) were incubated with 10 nM [‘H]AVP for 30 min 
at 3O*C and then incubated for a further 30 min in the presence or 
absence (control) of 1 mM NEM. For the ligand protection studies, 
bovine kidney membranes (100 ,ag protein in 100 ~1 binding buffer) 
were preincubated with saturating concentrations of the peptide 
ligand for 30 mln at 3O’C. After incubation with ligand, the mem- 
brane suspension was incubated with 1 mM NEM for a further 30 
min. The membranes were then collected by centrifugation, and 
resuspended in an equal volume (100 $1) of 250 mM ammonium- 
acetate buffer, pH 5.5, to allow bound ligand to dissociate from the 
receptor. After 5 min at 3O”C, these membranes were washed with 
binding buffer and binding tests were performed. For the receptor 
binding saturation assays, increasing concentrations of 13H]AVP 
were used in the presence (non-specific binding) or in the absence 
(total binding) of an lOO-fold excess of AVP. 
The LLC-PKi porcine kidney epithelial, and A7r5 rat aortic 
smooth muscle cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% (v/v) foetal calf serum, 0.2 mg/ml 
steptomycin and 50 U/ml penicillin, and [3HJAVP binding tests were 
performed on cell monolayers as previously described 1121. Cell 
monolayers were preincubated in the presence or absence (control) of 
1 mM NEM for 30 min at 30°C, and after removal of the sulfhydryl 
reagent containing medium they were further incubated with 10 nM 
[3H]AVP in the presence (non-specific binding) or in the absence 
(total binding) of 1 FM AVP in DMEM for 60 min at 4°C. (This in- 
cubation was performed at a lower temperature to prevent inter- 
nalization of the receptors.) 
All assays were performed in triplicate. The experiments were per- 
formed two times. Binding curves were fitted to a logistic function 
with a weighted iterative least-squares procedure based on the method 
of steepest descent [lo]. The figures and tables show representative ex- 
periments. The standard deviation from the mean is indicated in the 
figures. 
2.3 ~ete~inat~o~ f the sta~i~~t~ of f)H]A VP by HPLC 
Membranes (containing 1 mg of protein) in 1 ml of binding assay 
buffer were incubated with 1 mM NEM and 10 nM [3H]AVP for 30 
min at 30% After incubation, the membranes were pelletted by cen- 
trifugation for 10 min at 10000 x g. The supernatant was then sub- 
jected to chromatography (Varian 5000 Liquid Chromatograph) on a 
Knauer LiChrosorb 10 RP18 HPLC column (250 x 4 mm) with a 20 
ml linear gradient of 18% to 72% acetonitrile in 0.~~0 t~fluoroacetic 
acid at a flow rate of 1 ml/min. The fractions were analysed for 
radioactivity in order to determine the retention time of the radioac- 
tive material. The retention time for unlabelled AVP (8.9 min) was 
determined separately under the same conditions, using absorbance at 
220 nm to detect the eluting AVP. 
3. RESULTS 
3.1. Effect ofpretreatment with suifiydryl reagents on 
the specific binding of PHJAVP to bovine V2 
receptors 
Preincubation of bovine kidney membrane with p- 
CMBS, NEM and IAA gives rise to concentration- 
dependent inactivation of the VZ binding sites (Fig. 1). 
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Fig. 1. Effect of sulfhydryl reagents on the specific binding of 
[‘H]AVP to the VZ vasopressin receptor in bovine kidney membranes. 
Membranes were preincubated with increasing concentrations of IAA 
(A), NEM (e) and p-CMBS (a) as described in section 2 before 
measuring [3H]AVP binding capacity. Results are expressed as a 
percentage of the control (100% = 1.3 pmol/mg protein). 
With all three reagents, a maximal, irreversible effect 
occurs within 30 min. The most effective inactivating 
agent is p-CMBS. Higher concentrations of p-CMBS, 
and also of NEM, lead to total inactivation of the recep- 
tor. IAA, as a less potent sulfhydryl reagent, decreases 
specific binding to a lesser extent, even at higher con- 
centrations. All experiments hown here were perform- 
ed in buffer at pH 8.2, the optimal pH for the receptor- 
ligand interaction. The experiments were also perform- 
ed at pH 7.0, the optimum pH for sulfhydryl group 
alkylation by the reagents [5]. The results (data not 
shown), were similar to those obtained at pH 8.2. When 
membranes were concurrently treated with E3H]AVP 
and NEM and then extracted, all of the radioactivity 
recovered had the same retention time as unlabelled 
AVP, on HPLC, excluding the possibility that the 
radioactive AVP is chemically modified after incuba- 
tion with NEM. 
Treatment of bovine renal membranes with 1 mM 
NEM causes a 79.1% reduction in vasopressin binding 
sites (Fig. 2). The dose-dependent binding experiments 
demonstrate that alkylation of sulfhydryl groups com- 
pletely abolishes binding to those VZ receptors that are 
modified. The affinity of the remaining bovine kidney 
V2 receptors for AVP in NEM-treated membranes is 
unchanged. The remaining vasopressin binding sites ap- 
pear to be homogenous, as the dose-dependent binding 
curves generated linear Scatchard plots (results not 
shown). The difference between the equi~brium 
dissociation constants of the untreated Vt receptors 
(& = 0.98 f0.19 nM) and the receptors treated by NEM 
(& = 1.35 f 0.21) is not significant. 
3.2. Effect of preincubation with various iigunds on 
Nap-induced VZ receptor inuctivation 
The receptor-ligand complexes in bovine kidney 
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Fig. 2. Effect of NEM on the dose-dependent binding of [3H]AVP to 
the bovine renal Vz vasopressin receptor. The results show the concen- 
tration of specific [3H]AVP binding sites of the untreated membranes 
(0) and of membranes after treatment with 1 mM NEM (0). The 
reaction of membranes with 1 mM NEM and binding of [‘HIAVP was 
performed as described in section 2. 
membranes, formed by preincubation with 10 nM We have studied the influence of several suXhydry1 
[3H]AVP, do not dissociate after 30 min treatment with group-alkylating agents, on VI and VZ receptors in in- 
1 mM NEM, 105.8& 14.6% of the receptor binding tact cells and in isolated membranes investigating the 
sites being occupied with respect to the untreated con- effect of NEM in greater detail. We found that NEM, 
trol. Pretreatment of the bovine kidney membranes p-CMBS and IAA inactivate VZ binding sites in a dose- 
with agonists (ligands 1-3, Table I), or antagonists dependent manner in bovine kidney membranes. This 
(ligands 4 and 5 [ 131, in Table I) at concentrations inactivation by NEM markedly reduces the number of 
which correspond to approximately 10 times their Kd- binding sites without altering the affinity of unmodified 
values virtually completely protects the VZ receptor receptor molecules. Our results suggest hat this effect 
from NEM-induced inactivation (Table I). is due to a direct reaction of NEM with VZ receptor 
3.3. Comparison of NEWtreated VI and V2 
vasopressin receptors in isolated membranes and 
in established cell lines 
The VZ receptor of porcine kidney membranes is inac- 
tivated by pretreatment with 1 mM NEM to a similar 
extent as the VZ receptor of bovine membranes. The rat 
liver VI receptor, on the other hand, is relatively stable 
to pretreatment with 1 mM NEM (Table II). In all 
cases, treatment with NEM results in a reduced number 
of binding sites but does not affect the affinity for AVP 
(Kd values not shown) of the remaining binding sites. 
The sensitivity of the VI- receptor of A7r5 rat smooth 
muscle cells and of the VZ receptor of LLC-PK1 porcine 
kidney epithelial cells to NEM treatment correlates with 
the results found in membrane preparations. Generally, 
VZ receptors are inactivated to a much greater extent 
(approximately lo-20% of binding activity remaining) 
than VI receptors (approximately 70-90% of binding 
activity is remaining, Table II). 
4. DISCUSSION 
Table 1 
Protection against NEM-induced inactivation of bovine VZ membrane receptors by pretreatment with vasopressin agonists and antagonists (con- 














Receptor binding remaining after 
preincubation with ligands (% of control) 
17 f 4 
95 + 2 
91 + 4 
97 f 2 
96 + 6 
101 f 5 
Table II 
Effect of pretreatment with 1 mM NEM on the binding of 13H]AVP to V2 and VI vasopressin isoreceptors (control: binding capacity without NEM 
pretreatment) 
Receptor subtype Binding capacity Receptor binding remaining after 
(fmol/mg protein) treatment with NEM (% of control) 
Control 1 mM NEM pretreatment 
V2 (bovine kidney membranes) 1312 + 16 274 f 4 20.9 
VZ (pig kidney membranes) 549 f 9 50 f 12 9.1 
V2 (LLC-PKI cells) 204 f 7 33 + 5 16.2 
VI (rat liver membranes) 653 + 8 570 f 10 87.3 
VI (A7r5 cells) 148 f 5 107 f 7 72.3 
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molecules and not with G proteins, since intact G pro- 
teins are necessary for the receptor conformation with 
highest binding affinity. GTP and non-hydrolysable 
analogues, via G proteins, reduce the ligand affinity of 
bovine kidney membrane VZ binding sites by a factor of 
2-3 [14]. Other VZ receptors (in porcine kidney mem- 
branes and in LLC-PKI cells) are similarly inactivated 
by NEM. Our results show that is is possible to use 
NEM to differentiate between vasopressin isoreceptors. 
The different reactivities of Vl and VZ receptors may 
be explained in terms of difference in primary struc- 
tures. The VZ receptor molecules could have one or 
more exposed cysteine residues which should be intact 
for the binding activity. Our data suggest that 
sulfhydryl groups are located in, or close to, the ligand- 
binding domain of the VZ receptor and can be protected 
by preincubation with vasopressin agonists or an- 
tagonists. Another possible explanation of the results of 
the ligand protection experiments is that the binding of 
a specific ligand to the VZ receptor can change the 
receptor conformation in such a way that critical 
sulfhydryl groups become less accessible to NEM. The 
protection against inactivation with the carba analogue 
[Asu , lv6 Arg’lvasopressin lacking a disulfide moiety 
suggests that protection by vasopressin analogues is not 
through a direct chemical reaction of the analogues’ 
sulfhydryl groups with a sulfhydryl group of the recep- 
tor molecule. 
Sulfhydryl group-alkylating agents have been used to 
investigate vasopressin induced water channels. The 
direct effects of NEM, p-CMBS, HgC12, IAA and other 
reagents on the water pathways in the luminal mem- 
brane of kidney proximal tubule [ 151 and in the luminal 
membrane of the frog urinary bladder [2-41 are well 
established. Less attention was paid, in these studies, to 
the direct effect of the sulfhydryl-alkylating agents on 
the vasopressin receptors. In an earlier study it was 
shown that NEM added to the serosal solution of the 
isolated toad bladder in concentrations greater than 1 
mM completely inhibited the effect of vasopressin [161. 
Our results suggest hat this effect could be explained by 
a direct inactivation of vasopressin receptor molecules. 
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